Literature DB >> 16940508

Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry.

Aravind Asokan1, Julie B Hamra, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Richard J Samulski.   

Abstract

Integrins have been implicated as coreceptors in the infectious pathways of several nonenveloped viruses. For example, adenoviruses are known to interact with alphaV integrins by virtue of a high-affinity arginine-glycine-aspartate (RGD) domain present in the penton bases of the capsids. In the case of adeno-associated virus type 2 (AAV2), which lacks this RGD motif, integrin alphaVbeta5 has been identified as a coreceptor for cellular entry. However, the molecular determinants of AAV2 capsid-integrin interactions and the potential exploitation of alternative integrins as coreceptors by AAV2 have not been established thus far. In this report, we demonstrate that integrin alpha5beta1 serves as an alternative coreceptor for AAV2 infection in human embryonic kidney 293 cells. Such interactions appear to be mediated by a highly conserved domain that contains an asparagine-glycine-arginine (NGR) motif known to bind alpha5beta1 integrin with moderate affinity. The mutation of this domain reduces transduction efficiency by an order of magnitude relative to that of wild-type AAV2 vectors in vitro and in vivo. Further characterization of mutant and wild-type AAV2 capsids through transduction assays in cell lines lacking specific integrins, cell adhesion studies, and cell surface/solid-phase binding assays confirmed the role of the NGR domain in promoting AAV2-integrin interactions. Molecular modeling studies suggest that NGR residues form a surface loop close to the threefold axis of symmetry adjacent to residues previously implicated in binding heparan sulfate, the primary receptor for AAV2. The aforementioned results suggest that the internalization of AAV2 in 293 cells might follow a "click-to-fit" mechanism that involves the cooperative binding of heparan sulfate and alpha5beta1 integrin by the AAV2 capsids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940508      PMCID: PMC1563945          DOI: 10.1128/JVI.00843-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  Cell receptors involved in adenovirus entry.

Authors:  G R Nemerow
Journal:  Virology       Date:  2000-08-15       Impact factor: 3.616

2.  Integrin alpha(v)beta1 is an adenovirus coreceptor.

Authors:  E Li; S L Brown; D G Stupack; X S Puente; D A Cheresh; G R Nemerow
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity.

Authors:  N Kaludov; K E Brown; R W Walters; J Zabner; J A Chiorini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  The cellular receptor to human rhinovirus 2 binds around the 5-fold axis and not in the canyon: a structural view.

Authors:  E A Hewat; E Neumann; J F Conway; R Moser; B Ronacher; T C Marlovits; D Blaas
Journal:  EMBO J       Date:  2000-12-01       Impact factor: 11.598

5.  Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.

Authors:  P Wu; W Xiao; T Conlon; J Hughes; M Agbandje-McKenna; T Ferkol; T Flotte; N Muzyczka
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation.

Authors:  S Sanlioglu; P K Benson; J Yang; E M Atkinson; T Reynolds; J F Engelhardt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin alpha5beta1: influence of the leucine residue within the RGDL motif on selectivity of integrin binding.

Authors:  T Jackson; W Blakemore; J W Newman; N J Knowles; A P Mould; M J Humphries; A M King
Journal:  J Gen Virol       Date:  2000-05       Impact factor: 3.891

9.  Identification of PDGFR as a receptor for AAV-5 transduction.

Authors:  Giovanni Di Pasquale; Beverly L Davidson; Colleen S Stein; Inês Martins; Dominic Scudiero; Anne Monks; John A Chiorini
Journal:  Nat Med       Date:  2003-09-14       Impact factor: 53.440

10.  Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry.

Authors:  Kirsten A Weigel-Kelley; Mervin C Yoder; Arun Srivastava
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

View more
  82 in total

1.  Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction.

Authors:  Paul M Kaminsky; Nicholas W Keiser; Ziying Yan; Diana C M Lei-Butters; John F Engelhardt
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

Review 2.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

3.  Molecular cloning, overexpression, and an efficient one-step purification of α5β1 integrin.

Authors:  Lawrence J Tartaglia; Antonette Bennett; Alexander S Plattner; Nicholas Muzyczka; Chen Ling; Arun Srivastava; Mavis Agbandje-McKenna
Journal:  Protein Expr Purif       Date:  2013-08-29       Impact factor: 1.650

Review 4.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 5.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

Review 6.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

7.  Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

Authors:  Jason O'Donnell; Kenneth A Taylor; Michael S Chapman
Journal:  Virology       Date:  2009-01-13       Impact factor: 3.616

8.  Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.

Authors:  Chengwen Li; Yi He; Sarah Nicolson; Matt Hirsch; Marc S Weinberg; Ping Zhang; Tal Kafri; R Jude Samulski
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

Review 9.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

10.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.